Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates
Standard
Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. / Loges, Sonja; Schmidt, Thomas; Carmeliet, Peter.
In: Genes Cancer, Vol. 1, No. 1, 01.2010, p. 12-25.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates
AU - Loges, Sonja
AU - Schmidt, Thomas
AU - Carmeliet, Peter
PY - 2010/1
Y1 - 2010/1
N2 - The concept of inhibiting tumor neovessels has taken the hurdle from the bench to the bedside and now represents an extra pillar of anticancer treatment. So far, anti-angiogenic therapy prolongs survival in the order of months in some settings while failing to induce a survival benefit in others, in part because of intrinsic refractoriness or evasive escape. This review provides an update on recent mechanisms via which tumor and stromal cells induce resistance and discusses recent evolutions in the (pre)clinical development of novel third-generation anti-angiogenic agents to overcome this problem.
AB - The concept of inhibiting tumor neovessels has taken the hurdle from the bench to the bedside and now represents an extra pillar of anticancer treatment. So far, anti-angiogenic therapy prolongs survival in the order of months in some settings while failing to induce a survival benefit in others, in part because of intrinsic refractoriness or evasive escape. This review provides an update on recent mechanisms via which tumor and stromal cells induce resistance and discusses recent evolutions in the (pre)clinical development of novel third-generation anti-angiogenic agents to overcome this problem.
KW - Journal Article
U2 - 10.1177/1947601909356574
DO - 10.1177/1947601909356574
M3 - SCORING: Journal article
C2 - 21779425
VL - 1
SP - 12
EP - 25
JO - Genes Cancer
JF - Genes Cancer
SN - 1947-6019
IS - 1
ER -